Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app boost quality of life for young cancer patients?

NCT ID NCT05350631

Symptom relief Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will compare app users to non-users over 6 months, focusing on emotional and social well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OnKO-Tips&Tricks digital phone application
What this could lead to
If it works, this app could help teens and young adults with cancer feel better emotionally and socially, and make it easier to manage their care.
What could go wrong
This is a relatively small study (200 people) testing a support tool, not a treatment. The app may not significantly improve quality of life, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient age ≥ 15 years and ≤ 25 years * Diagnosed with solid or blood cancers less than 1 month old or patient with relapsed cancer more than 5 years after completion of initial treatment * Follow-up at one of the participating study centers * Informed and signed consent from the patient and, if the subject is a minor, from the holders of parental authority * Inclusion in the study at the latest at the time of initiation of chemotherapy or radiotherapy * Patient agrees to 12-month post-inclusion follow-up * Patient agreeing to complete all study questionnaires * Patient with a cellphone capable of downloading the app (developed for all types of cellphones) * Affiliated to a social health insurance plan Exclusion Criteria: * Patient deprived of liberty by a judicial or administrative decision * Patient with protected person status * Patient who does not understand, speak or write French * Patient unable to understand the follow-up protocol according to the investigating physician or the IDEC of the AJA unit * Patient with a scheduled hospitalization of at least 5 weeks during study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Marseille

    Marseille, 13005, France

  • CHU Reims - Hôpital Maison Blanche

    Reims, France, 51092, France

  • CHU Rennes Hôpital Sud

    Rennes, 35200, France

  • CHU de Nice Hôpital Archet 2

    Nice, France, 06202, France

  • Hôpital enfant-adolescent

    Nantes, France, 44093, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France, 67091, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut d'Hématologie et d'Oncologie Pédiatrique

    Lyon, France, 69 008, France

  • Institut de Cancerologie Strasbourg Europe

    Strasbourg, 67200, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.